Anticancer Drugs Market Size, Share & Analysis Report, 2022-2030
According to Nova one advisor, the global Anticancer Drugs market was valued at USD 145.18 billion in 2021 and it is expected to hit around USD 256.70 billion by 2030 with a CAGR of 7.80% during the forecast period 2022 to 2030.
One of the leading causes of death is cardiovascular diseases followed by cancer. It is estimated that 1 out of 6 deaths is caused due to cancer. Within 3 years of the discovery of cancer its antidrug was invented hence proving that medical science has made enormous advances. On account of the growing demand for cancer curing drugs worldwide, the pharmaceuticals market, especially with regard to anti-cancer drugs is on hike.
The Global market for anticancer drugs comprises of a highly aggressive vendor landscape. In view of a number of the largest leading pharmaceutical players of the world, the market is fragmented. The leading companies compete with innovative products and strong pipelines to boast the high efficacy and efficiency in the market. There is also a constant rise in the number of small players as they are focusing on innovative treatment methods.
Report Scope of the Anticancer Drugs Market
|
Report Coverage |
Details |
|
Market Size |
USD 256.70 Billion by 2030 |
|
Growth Rate |
CAGR of 7.80% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Drug Type, Therapy Type, Cancer Type, and Region, |
|
Companies Mentioned |
Amgen Inc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd |
Anti-cancer drugs with minimum Side-effects driving growth in the market
Based on therapy, the anticancer drug market is segmented into immunotherapy, targeted therapy and chemotherapy. Immunotherapy is usually for treating melanoma, a dangerous form of skin cancer. The segment for targeted drugs accounts for more than 50% of share value in the global drugs market for anti-cancer. As compared to cytotoxic drugs, minimum side effects along with effective results and high specificity of the drugs are predicted to expand the growth of the segment by 2030.
On the basis of cancer type, there is colorectal cancer, breast cancer, leukemia and lung cancer out of which lung cancer is predicted to expand at a strong CAGR of over 9% due to large number of lung cancer incidences and high prevalence and promising pipeline for non-small cell lung cancer (NSCLC) drugs during the forecast period.
North America to Contribute Large Share in Future with Private and Public Sector Support
The global anticancer drugs market is studied on the basis of key geographies Middle East and Africa, Latin America, Asia Pacific, Europe, and North America. Among these, Germany, U.K. and U.S. show higher adoption for anti-cancer drugs compared to other regions. This is because of the prevalence of unhealthy lifestyle, developed healthcare infrastructure, targeted efforts of government and NGOs towards cancer management.
North America is expected to grow at a rapid pace during the forecast period other than Japan and Australia which seems favorable for the market growth. Increased awareness regarding the benefits of early diagnosis, rising disposable incomes, rising prevalence of number of forms of cancer, and projected pipeline drugs are propelling the growth of the regional market. Due to the easy availability of drugs in the region, and high healthcare expenditure from both the private and public sector, North America is predicted to contribute largely to the anticancer drugs market globally. Apart from that, established players are entering China and India due to high prevalence making the market attractive. The markets in other regions such as Africa, Middle East and Latin America are expected to grow during the forecast period at moderate rate.
Endorsements from Provincial Administrative Bodies will Boost Anticancer Drugs Market
The increasing number of deaths caused due to cancer is a prime factor augmenting the growth of the global anticancer drugs market. Cancer is a gathering of sicknesses related with strange cell development with the possibility to torment or spread to different pieces of the body. Significant sorts of tumors incorporate carcinomas, sarcomas, lymphomas, and leukemia. Sarcomas start in the connective tissue like muscle or bones. Delicate tissue sarcomas can start in greasy tissues. Additionally, the therapy of malignancy in patients requires the utilization of various drugs like hormonal treatment, immunotherapy, directed treatment, and others.
Moreover, natural drugs based on monoclonal antibodies (mAbs) have arisen as a favored alternative to treat different malignancy types, particularly blood disease (leukemia). Ascend in frequency of different disease conditions, expansion in ubiquity of advance treatments (organic and focused on drug treatments), and flood in geriatric populace overall are the key components driving the development of the worldwide oncology/malignancy drugs market. Moreover, ascend in malignancy mindfulness and accessibility of disease drugs are required to support the market development.
The development of the worldwide oncology/malignancy drugs market is significantly determined by expansion in rate of different disease conditions, ascend in ubiquity of advance treatments (natural and focused on drug treatments), and flood in geriatric populace around the world. Moreover, ascend in disease mindfulness and accessibility of malignancy drugs are required to help the market development. In any case, significant expense engaged with new medication advancement combined with danger of disappointment and unfriendly impacts related with malignancy drugs treatments is required to control the development of the market. Then again, high capability of arising economies and expansion in number of pipeline items are required to give new freedoms to advertise major parts in future.
On the contrary, high cost of therapies and severe unofficial laws are required to control the worldwide enemy of malignant growth drug market later on. Drug associations face difficulties in recuperating the immense expense engaged with new item advancement. These drugs have a danger of results which are required to hamper in general item interest in the coming years.
Nevertheless, drug associations are focusing on creating new medications to address buyer issues. Medication endorsement from provincial administrative bodies is a significant development factor and in this way support from the local government bodies and non-benefit associations is relied upon to drive worldwide enemy of disease drug market interest over the estimate time frame.
Some of the prominent players in the Anticancer Drugs Market include:
Amgen Inc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Anticancer Drugs market
Drug Type
Therapy Type
Cancer Type
By Geography
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anticancer Drugs Market
5.1. COVID-19 Landscape: Anticancer Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anticancer Drugs Market, By Drug Type
8.1. Anticancer Drugs Market, by Drug Type, 2022-2030
8.1.1 Lithium
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Lead
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Cheese
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Dessert
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anticancer Drugs Market, By Therapy Type
9.1. Anticancer Drugs Market, by Therapy Type, 2022-2030
9.1.1. Cathode
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Anode
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Electrolyte
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Separator
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anticancer Drugs Market, By Cancer Type
10.1. Anticancer Drugs Market, by Cancer Type, 2022-2030
10.1.1. Consumer
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Automotive
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Industrial
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Cheese
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Anticancer Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.1.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.2.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.3.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.4.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.5.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Therapy Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Cancer Type (2017-2030)
Chapter 12. Company Profiles
12.1. Amgen Inc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Takeda Pharmaceutical Company Limited
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers